Simply Wall St.
What Recent Price Target Signals For The Evolving Nektar Therapeutics (NKTR) Story
📊
AI Sentiment
Positive
6/10
- Home
- NKTR
NKTR
Nektar Therapeutics
as of 01-22-2026 3:46pm EST
$36.10
$0.82
-2.22%
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 807.8M | IPO Year: | 1994 |
| Target Price: | $111.83 | AVG Volume (30 days): | 688.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.48 - $66.92 | Next Earning Date: | 03-11-2026 |
| Revenue: | $62,600,000 | Revenue Growth: | -32.79% |
| Revenue Growth (this year): | -54.92% | Revenue Growth (next year): | -3.79% |
AI-Powered NKTR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
Zalevsky Jonathan
Sell
Chief R&D Officer
NKTR Jan 20, 2026
Avg Cost/Share
$35.67
Shares
3,867
Total Value
$137,935.89
Owned After
21,354
SEC Form 4
Wilson Mark Andrew
Sell
Chief Legal Officer
NKTR Nov 25, 2025
Avg Cost/Share
$54.28
Shares
630
Total Value
$34,196.40
Owned After
21,585
SEC Form 4
ROBIN HOWARD W
Sell
President & CEO
NKTR Nov 25, 2025
Avg Cost/Share
$54.28
Shares
2,207
Total Value
$119,795.96
Owned After
54,245
SEC Form 4
Zalevsky Jonathan
Sell
Chief R&D Officer
NKTR Nov 25, 2025
Avg Cost/Share
$54.28
Shares
1,157
Total Value
$62,801.96
Owned After
21,354
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Jan 20, 2026 | Sell | $35.67 | 3,867 | $137,935.89 | 21,354 | |
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Nov 25, 2025 | Sell | $54.28 | 630 | $34,196.40 | 21,585 | |
| ROBIN HOWARD W | NKTR | President & CEO | Nov 25, 2025 | Sell | $54.28 | 2,207 | $119,795.96 | 54,245 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Nov 25, 2025 | Sell | $54.28 | 1,157 | $62,801.96 | 21,354 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
Compare NKTR vs Leading Stocks
See how NKTR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.